Retatrutide clinical trials
Retatrutide is named as an intervention in 11 current clinical trials in our USA, Canada, UK, Germany, Poland, Mexico, Brazil, Israel, India, France, Spain, Italy, Netherlands, Belgium, Austria, Czechia, Turkey, Australia, China, Denmark, Sweden, Switzerland, Norway, Portugal, Japan, South Korea and Taiwan registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Eli Lilly and Company (10). The most-studied condition is Obesity.
How Retatrutide works
All drug targets →- Glucagon receptor agonist AgonistTarget: GCGR glucagon receptor✓ In ChEMBL and the Guide to Pharmacology
- Glucagon-like peptide 1 receptor agonist AgonistTarget: GLP1R glucagon like peptide 1 receptor✓ In ChEMBL and the Guide to Pharmacology
- Gastric inhibitory polypeptide receptor agonist AgonistTarget: GIPR gastric inhibitory polypeptide receptor✓ In ChEMBL and the Guide to Pharmacology
- OverweightPhase 3
- Cardiovascular disorderPhase 3
- Obesity disorderPhase 3
- OsteoarthritisPhase 3
- Type 2 diabetes mellitusPhase 3
- Chronic kidney diseasePhase 2
- HypoglycemiaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095485, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13769, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Retatrutide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Retatrutide
- ChEMBL
- CHEMBL5095485
- FDA UNII
- NOP2Y096GV
- Wikidata
- Q120468350
- Wikipedia
- Retatrutide
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Retatrutide
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Retatrutide
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 10 |
| Hudson Biotech | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Retatrutide trials
How many clinical trials are testing Retatrutide?
11 current trials in our USA, Canada, UK, Germany, Poland, Mexico, Brazil, Israel, India, France, Spain, Italy, Netherlands, Belgium, Austria, Czechia, Turkey, Australia, China, Denmark, Sweden, Switzerland, Norway, Portugal, Japan, South Korea and Taiwan registers name Retatrutide (also registered as LY3437943) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Retatrutide trials recruiting patients?
Yes. 2 of the 11 trials are recruiting: 1 with sites in USA, 1 with sites in Canada, 1 with sites in UK, 1 with sites in Germany, 1 with sites in Poland, 1 with sites in Mexico, 1 with sites in Brazil, 1 with sites in Israel, 1 with sites in India, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Turkey, 1 with sites in Australia, 2 with sites in China, 1 with sites in Sweden, 1 with sites in Switzerland, 1 with sites in Norway, 1 with sites in Portugal, 1 with sites in Japan, 1 with sites in South Korea and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Retatrutide clinical trials?
Eli Lilly and Company (10) and Hudson Biotech (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Retatrutide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Retatrutide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Retatrutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.